Insider Selling: Boston Scientific Corporation (BSX) EVP Sells 85,227 Shares of Stock

Boston Scientific Corporation (NYSE:BSX) EVP Joseph Michael Fitzgerald sold 85,227 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $26.48, for a total value of $2,256,810.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up $0.22 during midday trading on Friday, reaching $25.42. The company’s stock had a trading volume of 1,268,451 shares, compared to its average volume of 9,674,697. Boston Scientific Corporation has a 12-month low of $23.29 and a 12-month high of $29.93. The firm has a market capitalization of $34,600.00, a PE ratio of 363.14, a P/E/G ratio of 1.91 and a beta of 0.81. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.34. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The business had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.39 billion. During the same period in the prior year, the company posted $0.30 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. research analysts anticipate that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.

BSX has been the subject of several analyst reports. BMO Capital Markets upped their target price on Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. SunTrust Banks set a $33.00 price target on Boston Scientific and gave the company a “buy” rating in a research report on Monday, December 4th. Zacks Investment Research raised Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Friday, October 20th. Evercore ISI started coverage on Boston Scientific in a research report on Wednesday, January 3rd. They set an “in-line” rating and a $27.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a research report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $31.00.

Hedge funds and other institutional investors have recently modified their holdings of the business. Valeo Financial Advisors LLC bought a new position in Boston Scientific during the 3rd quarter valued at $138,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Boston Scientific in the third quarter valued at about $139,000. Cerebellum GP LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $126,000. Ironwood Investment Counsel LLC acquired a new stake in shares of Boston Scientific in the third quarter valued at about $204,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at about $204,000. 90.15% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit